Key facts
- TimeTrace Labs’s last known valuation is $14.4M (Dec 2025).
- It has raised $4.0M; the latest was Seed Round ($4.0M) in Dec 2025.
- Notable investors include Seedcamp, Fly Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for TimeTrace Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for TimeTrace Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TimeTrace Labs
Developer of a quantitative measurement and analytics platform designed to separate signal from noise in healthcare data. The company applies methods from quantitative finance, particle physics, applied mathematics, and neuroscience to transform high-volume, multimodal datasets from trials, studies, consumer devices, and health systems into precise, interpretable descriptors of biological variability and change, enabling drug developers, public health agencies, and clinical researchers to detect meaningful change earlier, generate deeper insights from existing data, and power compliant, API-delivered analytics across diseases, data types, and scales.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Website
- timetracelabs.com/
- Ownership
- Privately Held (backing)
TimeTrace Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TimeTrace Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TimeTrace Labs in its N-PORT filings yet. We sweep new filings monthly.